Stay updated with breaking news from Yi Lin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Today (2/19) the solar term enter "Rain". Chiu Yenlung, an international expert in Feng Shui and numerology, reminds us that this year's rain solar term is very special. It is a watershed in destiny..
How the NASA-lead SABERS initiative is advancing the battery technology needed to support electric flight.
Yi Lin, MD, PhD, discusses findings from the primary analysis of the phase 1/2 CARTITUDE-1 trial of the BCMA-targeting CAR T-cell therapy ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma.
Minimal residual disease negativity sustained for 6 months or longer with ciltacabtagene autoleucel prolonged duration of response and progression-free survival compared with minimal residual disease negativity sustained for less than 6 months in patients with heavily pretreated relapsed/refractory multiple myeloma.
Yi Lin, MD, PhD, discusses the patient characteristic for those with relapsed/refractory multiple myeloma who experienced sustained minimal residual disease negativity following treatment with ciltacabtagene autoleucel during the phase 1/2 CARTITUDE-1 trial.